
The Biotech Startups Podcast
ExcedrAudio
- Format:
- Podcast
- New episodes:
- Several times a week
- Typical length:
- about 30 minutes
- Latest episode:
About this show
The Biotech Startups Podcast by Excedr features weekly conversations with founders, scientists, and investors driving biotech innovation. Host Jon Chee dives into the challenges of building biotech startups, from pre-seed to IPO. New episodes every Monday and Thursday.
Covers: biotech, startups, life sciences, entrepreneurship, clinical trials, drug development, venture capital, lab equipment
Show details and episodes come from the publisher's public feed at feeds.fame.so. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
This podcast covers the challenges of building biotech startups, through talks with founders, scientists and investors. Recent episodes cover disease signals before symptoms, a $500 lab that launched a company, and a company that reached almost $100 million without venture funding.
Cosmos
Similar in subject
- Business Of Biotech
Both cover: biotech, drug development, clinical trials - The a16z Show
Both cover: startups, venture capital - Y Combinator
Both cover: startups, venture capital, entrepreneurship
Similar shows
Explore more
Episodes
Don't Build Your Own Cathedral: The Hidden Cost of Lab Space | Philip Borden (4/4)
· 43 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. “Don't build your own cathedral.” After more than two decades in healthcare investing, Philip Borden decided to become an operator. He explains how a conversation with longtime friend Jeff Behrens led him to Labshares and why the shared lab model immediately resonated with his experience watching biotech companies struggle with infrastructure. Philip breaks down the hidden costs of traditional lab leases, from equipment maintenance and utilities to medical waste, freezer alarms, and unused square footage. He explains how flexible space can help emerging companies stay focused on milestones while preserving critical capital. The conversation closes with lessons from Labshares' first day under new ownership, including the loss of a major customer, the evolution of the company's value proposition, and the importance of transparent relationships with vendors. Philip also reflects on resilience, family, and the advice from his father to dream big. Key Topics Covered: - Becoming a Biotech Operator - The Acquisition of Labshares - Shared Lab Space - Capital Efficiency - Total Cost of Lab Ownership - The Cathedral Problem - Flexible Contracts - Founder and Vendor Relationships - Search Funds and Private Equity - Resilience Through Biotech Cycles If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep275 Find our guest, Philip Borden, at these links: LinkedIn: https://www.linkedin.com/in/philipborden Website: https://www.labshares.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Labshares: https://www.labshares.com/ LabCentral: https://labcentral.org/ UW CoMotion: https://comotion.uw.edu/ Pacific Lake Partners: https://www.pacificlake.com/ Harvard Business School: https://www.hbs.edu/ Duke University: https://www.duke.edu/ Excedr Partner Network: https://www.excedr.com/partners Companies, Universities, & People Mentioned: Riverside Partners: https://www.riversidepartners.com Galen Partners: https://www.galen-partners.com Frazier Healthcare Partners: https://www.frazierhealthcare.com LabCentral: https://labcentral.org UW CoMotion: https://comotion.uw.edu Pacific Lake Partners: https://www.pacificlake.com Harvard Business School: https://www.hbs.edu Duke University: https://www.duke.edu Wells Fargo: https://www.wellsfargo.com JPMorgan: https://www.jpmorgan.com Moderna: https://www.modernatx.com Lyndra Therapeutics: https://www.lyndra.com Jeff Behrens: https://www.linkedin.com/in/jeffbehrens Paul Graham: https://www.paulgraham.com Timestamps: 00:00 Intro 01:43 The Post-2008 Crash and Changing LP Base 03:16 Riverside, Galen, and the Impact of COVID 04:25 How Jeff Behrens Started Labshares 05:19 Why Labshares Resonated with Philip 07:55 Let Scientists Focus on Science 10:01 The Total Cost of Owning Lab Space 11:54 From…
Not rated yetThe Biotech Deal That Became a Leadership Crisis | Philip Borden (3/4)
· 30 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. “Sometimes like it is not a straight line, man. You know, that things can go in wildly unexpected directions.” Philip Borden describes leaving Frazier Healthcare Partners for Harvard Business School, where the case method broadened his perspective beyond healthcare and investing. He explains why he returned to healthcare investing after graduation. At Riverside Partners, Philip moved from venture into private equity, focusing on control investments in profitable, founder-owned healthcare businesses. He discusses why the model fit his personality better than venture's power-law dynamics and high failure rate. Philip also revisits BioAgilytix, his first fully solo deal, where a founder conflict forced an unexpected leadership transition shortly after the investment. He shares lessons on crisis management, vulnerability, team trust, fundraising from LPs, and investing through the 2008 to 2009 downturn. Key Topics Covered: - Harvard Business School - The Case Method - Healthcare Investing - Transition From Venture to Private Equity - Control Investments - Founder-Owned Businesses - Riverside Partners - BioAgilytix - Leadership Transitions - Limited Partner Fundraising If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep274 Find our guest, Philip Borden, at these links: LinkedIn: https://www.linkedin.com/in/philipborden Website: https://www.labshares.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Harvard Business School: https://www.hbs.edu/ Duke University: https://www.duke.edu/ BioAgilytix: https://www.bioagilytix.com/ GSK: https://www.gsk.com/ JPMorgan: https://www.jpmorgan.com/ Yale University: https://www.yale.edu/ Excedr Partner Network: https://www.excedr.com/partners Companies, Universities, & People Mentioned: Frazier Healthcare Partners: https://www.frazierhealthcare.com Harvard Business School: https://www.hbs.edu MIT Sloan: https://mitsloan.mit.edu Oxford Bioscience Partners: https://www.oxfordbioscience.com Riverside Partners: https://www.riversidepartners.com GSK: https://www.gsk.com BioAgilytix: https://www.bioagilytix.com JPMorgan: https://www.jpmorgan.com Aetna Healthcare: https://www.aetna.com DeWalt Power Tools: https://www.dewalt.com Ducati Motorcycles: https://www.ducati.com SpaceX: https://www.spacex.com Yale: https://www.yale.edu David Swensen: https://en.wikipedia.org/wiki/David_Swensen Jeremy Griffin: https://www.linkedin.com Timestamps: 00:00 Intro 01:51 From Frazier to Harvard Business School 02:46 The Case Method and Socratic Learning 04:05 Building a Broader Business Foundation 05:38 Returning to Healthcare Investing 08:23 From Venture to Private Equity 12:37 Control Investments in Founder-Owned Businesses 14:32 Building Riverside's Healthcare Practice 15:36 Sourcing…
Not rated yetCold Calling Your Way Into Venture Capital | Philip Borden (2/4)
· 21 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. “What I could offer is I'm willing to work hard. I'm willing to learn. I'm willing to be a good contributor.” Philip Borden explains how realizing he did not want to pursue a PhD or spend his career at the lab bench led him toward venture capital. With a molecular biology degree, limited finance experience, and a list of biotech VC firms, he picked up the phone and cold-called his way into Frazier Healthcare in Seattle. Philip shares why personal relationships, phone calls, and in-person conversations matter more than email when building trust. He discusses selling as communication and listening, the humility required to ask for an opportunity, and the culture lessons he learned from working alongside experienced investors. He also explains why investors owe founders timely, respectful answers, including a clear no. The conversation closes with the small customer rituals Labshares uses to honor entrepreneurs, from ribbon cuttings to creating a fun place to work. Key Topics Covered: - Career Exploration - Molecular Biology - Cold Calling - Venture Capital - Frazier Healthcare - Personal Relationships - Phone Communication - Founder Respect - Investor Responsiveness - Customer Experience If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep273 Find our guest, Philip Borden, at these links: LinkedIn: https://www.linkedin.com/in/philipborden Website: https://www.labshares.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Labshares About Us: https://www.labshares.com/about-us Harvard Business School: https://www.hbs.edu/ Duke University: https://www.duke.edu/ University of Washington: https://www.washington.edu/ Amazon: https://www.amazon.com/ Companies, Universities, & People Mentioned: Frazier Healthcare Partners: https://www.frazierhealthcare.com Riverside Partners: https://www.riversidepartners.com Galen Partners: https://www.galen-partners.com Longfellow Healthcare Partners: https://www.longfellowhc.com Duke University: https://www.duke.edu Harvard Business School: https://www.hbs.edu Amazon: https://www.amazon.com Microsoft: https://www.microsoft.com Moderna: https://www.modernatx.com Alan Frazier: https://www.frazierhealthcare.com Nader Naini: https://www.frazierhealthcare.com Patrick Herron: https://www.frazierhealthcare.com Örn Almarsson: https://www.linkedin.com/in/ornalmarsson Timestamps: 00:00 Intro 01:31 Choosing Not to Pursue Graduate School 03:40 Finding a Path Into Venture Capital 04:10 Cold-Calling Frazier Healthcare 04:54 Why the Phone Still Matters 06:49 Selling as Communication and Listening 08:10 Humility and the Frazier Culture 09:47 Moving to Seattle 11:57 Learning Through Partner Meetings 12:26 Screening Deals and Meeting Entrepreneurs 12:55 Respecting Founders in Vulnerable Moments…
Not rated yetWhat Rural Indiana Can Teach Biotech Founders About Trust | Philip Borden (1/4)
· 17 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. “It's the relationships that have always mattered a lot more to me on selecting a partner on that front.” Philip Borden grew up in Plymouth, Indiana, in a family shaped by agriculture. He talks about his grandparents' farms, his father's work as an agricultural lender, and the early lessons he absorbed about local businesses and long-term relationships. At Duke, an introductory biology class sparked Borden's interest in molecular biology and the underlying causes of disease. He explains why he chose Duke, how swimming and campus life shaped the experience, and why the relationships he built there mattered as much as what he learned in the classroom. Borden also reflects on the growing importance of communication, trust, and social judgment in a workplace increasingly influenced by AI. He closes with the independent study that took him into his family's history through Oliver Borden's journals and rural Indiana life before the Civil War. Key Topics Covered: - Growing Up in Rural Indiana - Agriculture and Community Banking - Relationships Over Transactional Deals - Choosing Capital Partners - Discovering Molecular Biology - Studying Biology at Duke - Swimming and College Life - The Value of Personal Relationships - AI and Social Skills - Researching Family History If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep272 Find our guest, Philip Borden, at these links: LinkedIn: https://www.linkedin.com/in/philipborden Website: https://www.labshares.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Duke Cell & Molecular Biology: https://biology.duke.edu/undergraduate/major/concentrations/cell-molecular Molecular Biology: https://www.ncbi.nlm.nih.gov/books/NBK21054/ Borden Family Collection: https://archives.isl.lib.in.us/repositories/2/resources/110 William Wesley Borden Papers: https://indianahistory.org/wp-content/uploads/william-wesley-borden-papers-1824-1895.pdf Companies, Universities, & People Mentioned: Frazier Healthcare Partners: https://www.frazierhealthcare.com Riverside Partners: https://www.riversidepartners.com Galen Partners: https://www.galen-partners.com Longfellow Healthcare Partners: https://www.longfellowhc.com Duke University: https://www.duke.edu Harvard Business School: https://www.hbs.edu University of Chicago: https://www.uchicago.edu JPMorgan: https://www.jpmorgan.com DoorDash: https://www.doordash.com Google: https://www.google.com Oliver Borden: https://archives.isl.lib.in.us/repositories/2/resources/110 Timestamps: 00:00 Intro 03:06 Growing Up in Plymouth, Indiana 03:24 An Agricultural Family Background 03:28 Lessons From a Local Agricultural Lender 04:32 Why Relationships Matter More Than Twenty-Five Basis Points 05:13 Capital Partners and the Cost of a Bad Fit 08:17 Discovering Molecular…
Not rated yet🧬 Making Lab Data Actionable Through Automation | Nathan Clark Rerelease (4/4)
· 34 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. “The other half is, okay, what do you do with that? Because you just got a bunch of, you got this huge dump of uncontextualized lab data. What does it mean?” In this part of the podcast, Nathan Clark explains how Ganymede approaches data integration and automation in life sciences. He discusses why lab instruments and workflows require customized connectors, how a developer platform can help teams adapt integrations quickly, and why moving data online is only part of the challenge. Nathan also describes Ganymede's two-tier product approach, the role of scientific software engineers, and a consultative go-to-market strategy built around explanatory materials and custom demonstrations. He explains which biotech companies may benefit most from the platform and why data strategy becomes increasingly important as organizations grow. The conversation looks ahead to data products, asset utilization, predictive maintenance, automated quality-control checks, and the practical value of connecting multiple laboratory systems. Nathan also shares his perspective on incremental digital transformation, building toward AI with contextualized data, the mentors who shaped his career, and why he would have taken entrepreneurial risks sooner. Key Topics Covered: - Custom connectors for laboratory instruments - Data transformation and analysis workflows - Scientific software engineers - Ganymede's two-tier product model - Consultative sales and custom demos - Biotech data strategy and infrastructure - Why data lakes can become data swamps - Incremental automation before AI - Asset utilization and predictive maintenance - Automated quality-control checks If you enjoy The Biotech Startups Podcast, subscribe and leave us a review. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1518627361 Spotify: https://open.spotify.com/show/4Y4Zc8tJYq5Yxw1uH8nJ9A YouTube: https://www.youtube.com/@TheBiotechStartupsPodcast Website: https://www.excedr.com/podcast Find Nathan Clark at these links: LinkedIn: https://www.linkedin.com/in/nathan-clark-4b850134/ Website: https://ganymede.bio/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com/ Intro/Outro music: OkKyojin: https://flow.page/kyojin Resources & Articles: NIST Design of Experiments: https://www.itl.nist.gov/div898/handbook/pri/pri.htm AWS Data Lakes and Analytics: https://aws.amazon.com/big-data/datalakes-and-analytics/ Benchling Resources: https://www.benchling.com/resources Elemental Machines: https://elementalmachines.com/ Companies, Universities, & People Mentioned: Benchling: https://www.benchling.com/ Affirm: https://www.affirm.com/ Goldman Sachs: https://www.goldmansachs.com/ AWS: https://aws.amazon.com/ Elemental Machines: https://elementalmachines.com/ SAP: https://www.sap.com/ Salesforce: https://www.salesforce.com/ HubSpot: https://www.hubspot.com/ Ramp: https://ramp.com/ Benson, Ganymede co-founder; surname not stated Nikki, Affirm product manager; surname not stated Sanjay, Benchling product manager; surname not stated Timestamps: 00:00 Intro 02:06 Building the Technical Team 02:36 Why Lab Integrations Require Customization 04:01 Turning Raw Bioreactor Data Into Analysis 06:40 The Developer Platform and Two-Tier Product 07:07 Maintaining Fragile Integrations Quickly 08:28 Ganymede's Consultative…
Not rated yet🧬 Why Wet-Lab Data Needs More Than ETL | Nathan Clark Rerelease (3/4)
· 29 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. “What matters is that you say, okay, this sample is part of this program and that program is part of this area.” Nathan Clark walks through his work at Benchling, where he managed the Insights business intelligence product and helped develop an early machine learning effort. He explains why operational wet-lab data is fundamentally different from omics data, and why the relationships between samples, programs, instruments, locations, and people matter as much as the experimental results. The conversation then moves into product discovery in scientific software. Nathan contrasts high-volume experimentation at Affirm with the slower, more qualitative process of working with research labs, where product teams need to study customer behavior, understand hidden needs, and show users what structured data can make possible. He also discusses why adoption requires tangible demonstrations when a category has no established name or buying process. Nathan traces the thinking that led to Ganymede, including the problem of biotech companies rebuilding the same AWS infrastructure, instrument parsers, and data connectors. He describes the cost of data decay, the value of turning unstable experimental information into structured design-of-experiments data, and the need to make scientific knowledge easier to share instead of repeatedly recreating the wheel. Key Topics Covered: - Benchling Insights and business intelligence - Operational wet-lab data and relational models - Product research with scientists - Electronic lab notebooks and LIMS - Instrument integration and data pipelines - Design of experiments and data capture - Data decay in biotech - Sharing scientific knowledge If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Listen and subscribe to The Biotech Startups Podcast: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1518627361 Spotify: https://open.spotify.com/show/4Y4Zc8tJYq5Yxw1uH8nJ9A YouTube: https://www.youtube.com/@TheBiotechStartupsPodcast Website: https://www.excedr.com/podcast Find Nathan Clark at these links: LinkedIn: https://www.linkedin.com/in/nathan-clark-4b850134/ Website: https://ganymede.bio/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com/ Intro/Outro music: OkKyojin: https://flow.page/kyojin Resources & Articles: NIST, What is design of experiments?: https://itl.nist.gov/div898/handbook/pmd/section3/pmd31.htm NIST, What are the steps of DOE?: https://itl.nist.gov/div898/handbook/pri/section1/pri13.htm Journal of Biomedical Semantics, ELN data provenance: https://link.springer.com/article/10.1186/s13326-021-00257-x Snowflake, Modern data stack: https://www.snowflake.com/guides/modern-data-stack Companies, Universities, & People Mentioned: Salesforce: https://www.salesforce.com/ Snowflake: https://www.snowflake.com/ Databricks: https://www.databricks.com/ Fivetran: https://www.fivetran.com/ AWS: https://aws.amazon.com/ Ginkgo Bioworks: https://www.ginkgobioworks.com/ Timestamps: 00:00 Intro 01:43 Benchling Insights and Machine Learning 03:55 Why Operational Data Matters 04:26 Benchling as a Relational System 05:10 The Modern Data Stack for Wet Labs 07:27 Finding a Business in Data Integration 07:46 Product Management in the Lab 10:31 Learning From Customer Behavior 11:26 Getting…
Not rated yet🧬 Product Thinking, Scientific Progress, & the Work of Building | Nathan Clark Rerelease (2/4)
· 27 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. “The formative stages of a pre-seed startup are like no code allowed.” Nathan Clark explains why he left Goldman Sachs for a technology-focused role at Affirm, where he worked across capital markets and product management. He discusses how financial mechanics carried over into fintech, while working with software engineers pulled him deeper into systems, data, and debugging. The conversation then turns to product management. Nathan describes the discipline as understanding why a product should exist, grounding decisions in user needs, and translating research into what a team builds. His advice for early-stage founders is direct: stop coding until they've done enough customer research to understand the problem. Nathan also reflects on the difficulty of measuring willingness to pay, the decision to leave Affirm, and his frustration with the slow pace of scientific progress. He explains why that frustration led him toward biology and Benchling, including an early attempt to build a plasmid editor, and why improving science requires more than simply putting money into the system. Key Topics Covered: - Nathan's move from Goldman Sachs to Affirm - Capital markets and point-of-sale loans - Securitization, liquidity, and recycling capital - Working with software engineers - Product management and user needs - Customer interviews and market research - The no-code approach to early startup validation - Small product increments and willingness to pay - Leaving Affirm during the COVID and IPO period - The slowing pace of scientific progress - The cost and difficulty of developing FDA-approved drugs - AI safety, machine learning, and incremental progress - Why Nathan moved toward biology - Benchling and building a plasmid editor - Financial infrastructure for lab equipment If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep269 Find our guest, Nathan Clark, at these links: LinkedIn: https://www.linkedin.com/in/nathan-clark-4b850134/ Website: https://ganymede.bio/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com/ Intro/Outro music: OkKyojin: https://flow.page/kyojin Resources & Articles: Affirm: https://www.affirm.com/ ProductPlan, What Is Product Management?: https://www.productplan.com/learn/what-is-product-management/ National Center for Biotechnology Information, Drug Development: https://www.ncbi.nlm.nih.gov/books/NBK216501/ Benchling: https://www.benchling.com/ SnapGene: https://www.snapgene.com/ Machine Intelligence Research Institute: https://intelligence.org/ Companies, Universities, & People Mentioned: Goldman Sachs: https://www.goldmansachs.com/ Affirm: https://www.affirm.com/ PayPal: https://www.paypal.com/ Max Levchin: https://www.linkedin.com/in/max-levchin/ Benchling: https://www.benchling.com/ SnapGene: https://www.snapgene.com/ Machine Intelligence Research Institute: https://intelligence.org/ Ray Kurzweil: https://www.kurzweilai.net/ Patrick Collison:…
Not rated yet🧬 Execution, Liquidity, & Founder Lessons | Nathan Clark Rerelease (1/4)
· 36 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners “There's no secret. It really is just doing.” Nathan Clark reflects on the formative influence of his entrepreneurial father, who showed him that business and even home building are learned through research, effort, and execution rather than secret insight. Nathan also discusses his unconventional high school experience, his decision to study business and finance at the University of North Carolina, and the early interest in biology and futurism that stayed with him. Nathan explains how his quantitative interests led him to Goldman Sachs, where he worked on a collateralized loan obligation trading desk. He breaks down market making, liquidity, bid-ask spreads, inventory, risk management, and the importance of balancing books in an illiquid market. The conversation also explores the habits Nathan developed on the trading desk, including rigorous reconciliation, attention to detail, understanding the mechanics behind the numbers, and making disciplined decisions under pressure. He connects those lessons to entrepreneurship, emphasizing execution, diligence, capital allocation, and learning from other industries. Key Topics Covered: - Nathan's upbringing and entrepreneurial father - Execution over secret insight - Imposter syndrome and taking action - An unconventional high school and college path - Studying business, economics, and finance at UNC - Early interest in biology, futurism, and OpenWorm - Recruiting for investment banking versus trading - Goldman Sachs and collateralized loan obligation trading - Market making and providing liquidity - Bid-ask spreads, fair pricing, and bond liquidity - Risk management and balancing a trading book - Attention to detail and operational diligence - Transferable lessons for founders If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep268 Find our guest, Nathan Clark, at these links: LinkedIn: https://www.linkedin.com/in/nathan-clark-4b850134/ Website: https://ganymede.bio/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com/ Intro/Outro music: OkKyojin: https://flow.page/kyojin Resources & Articles: Ganymede: https://ganymede.bio/ OpenWorm: https://openworm.org/ UNC Kenan-Flagler Business School: https://www.kenan-flagler.unc.edu/ Goldman Sachs: https://www.goldmansachs.com/ Affirm: https://www.affirm.com/ Benchling: https://www.benchling.com/ Companies, Universities, & People Mentioned: Goldman Sachs: https://www.goldmansachs.com/ Affirm: https://www.affirm.com/ Benchling: https://www.benchling.com/ OpenWorm: https://openworm.org/ University of North Carolina: https://www.unc.edu/ Timestamps: 00:00 Intro 02:00 Early Life and Family Influence 03:06 No Secret to Business 03:30 Execution and Imposter Syndrome 07:53 Choosing an Entrepreneurial Path 09:03 Early Interest in Biology 11:11 Unconventional High School Experience 11:51 Choosing UNC 13:48 Business, Economics, and Finance 14:33 Joining Goldman Sachs 15:36 How Bond…
Not rated yet🧬 AI, Mechanisms, & the Next Wave of Drug Discovery | David Li Rerelease (4/4)
· 27 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners “Think bigger. Don't worry about what others are thinking about. Think about exactly what you want and then work like hell to try to make it happen.” David Li explains how a research question about mischaracterized drug targets became the starting point for Meliora Therapeutics. He describes how CRISPR experiments and follow-up biology challenged the accepted mechanism for cancer drugs, and how the company uses AI and machine learning to connect chemistry, biology, biomarkers, and patient populations. David also talks through the move from private equity and life sciences software into company building. He shares how Meliora built a founding team around computational science and drug discovery, why the company is focused on creating clinically differentiated assets, and how internal programs and external partnerships fit together. The conversation closes with fundraising in a more demanding biotech market, the psychological resilience required to lead through uncertainty, and Meliora's plans to move from seed toward a Series A. David also reflects on the Penn program that changed his path and offers one clear piece of advice: think bigger. Key Topics Covered: - The transition from private equity to founding Meliora Therapeutics - Jason Sheltzer's research on mischaracterized drug mechanisms - CRISPR knockout experiments and target validation - Using AI and machine learning to identify mechanisms of action - Connecting mechanism, chemistry, biomarkers, and patient populations - Building a computational platform alongside drug discovery capabilities - Meliora's transition into a full-stack therapeutics company - Traditional drug discovery workflows and their blind spots - Internal pipeline development and external partnerships - Fundraising discipline in a difficult biotech environment - Psychological resilience as a biotech leader - Thinking bigger and pursuing an independent path If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep267 Find our guest, David Li, at these links: LinkedIn: https://www.linkedin.com/in/david-li-9aa210b Website: https://www.melioratherapeutics.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Websitehttps://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: NCI: The Serendipitous Off-Target Explorer, Researcher Interview with Jason Sheltzer: https://www.cancer.gov/ccg/blog/2021/interview-off-target Y Combinator Co-Founder Matching: https://www.ycombinator.com/cofounder-matching Yale Ventures: Jason Sheltzer, PhD: https://ventures.yale.edu/node/3875 Companies, Universities, & People Mentioned: Jason Sheltzer: https://ventures.yale.edu/node/3875 KKR: https://www.kkr.com/ Benchling: https://www.benchling.com/ Yale: https://www.yale.edu/ Y Combinator: https://www.ycombinator.com/cofounder-matching Biogen: https://www.biogen.com/company.html University of Pennsylvania: https://www.upenn.edu/ Timestamps:…
Not rated yet🧬 De-Risking Biotech's Biggest Bets | David Li Rerelease (3/4)
· 20 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. “You need to be able to project into what will happen when you arrive at the finish line, if and when you arrive at the finish line.” In this part of the podcast, David Li, CEO and co-founder of Meliora Therapeutics, reflects on his experience helping build Everest Detection around the challenge of finding lung cancer earlier. He discusses the potential of a noninvasive, blood-based test, why lung cancer can be difficult to detect in blood, and how access to early-stage clinical samples helped the team investigate the problem. David also compares biotech development with software innovation. Instead of releasing a product, gathering customer feedback, and iterating quickly, life science teams have to define a product profile, test core hypotheses, and de-risk the path to a prototype. He explains how parallel experiments, decision trees, and the distinction between one-way and two-way decisions can help teams move with urgency without treating every choice as irreversible. The conversation closes with a look at fundraising and capital allocation in biotech, where time, money, and risk are closely linked. David shares why raising enough capital to run experiments in parallel can accelerate progress, and why knowing when a project will not reach its next value inflection point is one of a founder's most important responsibilities. Key Topics Covered: - The case for earlier lung cancer detection - Noninvasive blood-based diagnostics - Clinical samples and biological signals - Life science innovation versus software development - Biotech's slower, engineering-led business cadence - Balancing urgency with deliberate decision-making - Parallel experiments and decision trees - One-way and two-way decisions - Defining biotech product-market fit - De-risking core hypotheses - Fundraising and capital allocation - Value inflection points and knowing when to stop If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep266 Find our guest, David Li, at these links: LinkedIn: https://www.linkedin.com/in/david-li-9aa210b Website: https://www.melioratherapeutics.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: USPSTF Lung Cancer Screening Recommendation: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening Stemcentrx Acquisition Announcement: https://investors.abbvie.com/news-releases/news-release-details/abbvie-expand-oncology-presence-through-acquisition-stemcentrx Amazon 2016 Letter to Shareholders: https://www.aboutamazon.com/news/company-news/2016-letter-to-shareholders Everest Detection: https://everestdetection.com/ Companies, Universities, & People Mentioned: Stemcentrx: https://investors.abbvie.com/news-releases/news-release-details/abbvie-expand-oncology-presence-through-acquisition-stemcentrx Goldman Sachs: https://www.goldmansachs.com/…
Not rated yet🧬 Choosing Conviction Over Convention in Biotech | David Li Rerelease (2/4)
· 25 min
🧬 The Biotech Startups Podcast is powered by Excedr: helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. “I think having that internal conviction is everything.” In this part of the podcast, David Li reflects on leaving finance after realizing that an investing career would not give him the tangible impact he wanted. He explains what KKR taught him about business and patient needs, then describes the team-and-market test that led him to Benchling. David also discusses the timing behind Benchling’s growth, the rise of new cell and gene therapy workflows, and the luck involved in joining a company at the right moment. He shares what it meant to build sales, marketing, customer success, and culture from the ground up. He then looks back on the early-stage lessons that shaped his next move toward more directly patient-facing life science work, including the importance of conviction, strong teams, and seeing what winning looks like. Key Topics Covered: - Long-term career decision-making - Patient impact in life sciences - Evaluating early-stage teams and markets - Benchling’s life science informatics platform - Cell and gene therapy market timing - Luck, conviction, and career risk - Building early-stage teams - Sales and go-to-market in biotech software - Everest Detection and cancer early detection If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep265 Find our guest, David Li, at these links: LinkedIn: https://www.linkedin.com/in/david-li-9aa210b Website: https://www.melioratherapeutics.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Benchling Online Lab Notebook: https://www.benchling.com/notebook Benchling at MIT News: https://news.mit.edu/2016/benchling-google-docs-life-sciences-managing-sharing-data-1207 Cell and Gene Therapy Report: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies AbbVie and Stemcentrx Acquisition: https://investors.abbvie.com/news-releases/news-release-details/abbvie-expand-oncology-presence-through-acquisition-stemcentrx Everest Detection: https://everestdetection.com/ Companies, Universities, & People Mentioned: Goldman Sachs: https://www.goldmansachs.com/ KKR: https://www.kkr.com/ Benchling: https://www.benchling.com/ Stemcentrx: https://investors.abbvie.com/news-releases/news-release-details/abbvie-expand-oncology-presence-through-acquisition-stemcentrx AbbVie: https://www.abbvie.com/ Everest Detection: https://everestdetection.com/ Timestamps: 00:00 Intro 02:03 KKR, Recruiting, and Long-Term Career Thinking 03:03 Finding Patient Impact in Investing 03:57 The Personal Truth Behind a Career Switch 05:48 Choosing Early-Stage Entrepreneurship 06:33 The Team-and-Market Test 07:46 Digitizing the Lab’s Chaos 08:44 Benchling’s Market Timing 11:58 Luck, Networks, and the Right Wave 13:32 Conviction Behind the Leap 14:34 Learning Leadership at…
Not rated yet🧬 The Outsider Mindset Behind Successful Biotech Founders | David Li Rerelease (1/4)
· 30 min
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. "It's a tricky balance. You kinda have to be both an oddball out, but it's the combination of the two that's important. Being able to think independently is perhaps oftentimes the harder one to get right because you're growing up, you wanna fit in and have friends and be popular. But channeling that into a way that is really laser-focused on ultimately what you wanna do and the impact, those are things I think about all the time." David Li's journey begins in Wuhan, China, and takes him to Louisville, Kentucky, at age three, where he learned what it meant to be an outsider. Moving from one culture to another at a formative age taught him adaptability and self-confidence—qualities that would later define his approach to leadership and entrepreneurship. His early fascination with science, from reading biology textbooks cover to cover to conducting research at the University of Chicago while still in high school, set the stage for a career at the intersection of science and business. In this part of the podcast, David shares how the Roy Vagelos Life Sciences and Management dual degree program at the University of Pennsylvania opened his eyes to the possibilities of combining scientific discovery with business acumen. A pivotal summer internship with Arie Belldegrun at UCLA—during which Kite Pharma was born—planted the seed for his future in life sciences entrepreneurship. He also discusses his transition into finance, landing at Goldman Sachs, and the lessons learned from sitting in boardrooms alongside C-level executives at critical moments in companies' life cycles. David's experiences as an immigrant, researcher, and financier shaped his perspective in biotech. He reflects on the importance of being comfortable as an outsider, the value of mentorship, and how each step of his journey contributed to his eventual path toward co-founding Meliora Therapeutics. Key Topics Covered: - Childhood in China and Kentucky - Early passion for biology and chemistry - High school research at the University of Chicago - UPenn Life Sciences and Management Program - Kite Pharma internship with Arie Belldegrun - Investment banking at Goldman Sachs - Leadership and being comfortable as an outsider If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep264 Find our guest, David Li, at these links: LinkedIn: https://www.linkedin.com/in/david-li-9aa210b Website: https://www.melioratherapeutics.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Early Childhood Leadership: https://etd.ohiolink.edu/acprod/odb_etd/ws/send_file/send?accession=akron1744394447429272&disposition=inline Biology Research: https://biology.stanford.edu/academics/undergraduate-program/doing-research/biology-summer-undergraduate-research-program-bsurp UPenn Roy Vagelos Program: https://lsm.upenn.edu/curriculum/dual-degree Science…
Not rated yet🧬 This Ex-Googler Replaced a Whole Drug R&D Team | Javier Tordable (4/4)
· 59 min
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners "We not only run agents that do the computational chemistry for our customers, but we run agents for building our own systems." In this part of the podcast, Javier Tordable unpacks why he left Google to solo found Pauling AI and how its agentic platform automates computational chemistry—from docking to ADMET—collapsing months into days. Javier walks through building a company alone with AI: filing patents with LLMs, writing sales processes, and running agents to build the systems customers depend on. He and Jon dig into why human-written communication will command a premium and how biotechs use Pauling to run screens faster. Looking ahead, Javier outlines a vision for unbiased AI that explores targets and modalities—small molecules today, peptides and antibodies tomorrow—in autonomous loops measured in days, not years. Key Topics Covered: - Leaving Google to Found Pauling AI - Automating Computational Chemistry with Agents - Solo Founding in the Age of AI - Agents Building the Builders - Go-to-Market Realities - Physics-Based Multi-Modality Vision - Economics Over Pure Science If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep263 Find our guest, Javier Tordable at these links: LinkedIn: https://www.linkedin.com/in/jtordable Website: https://www.pauling.ai/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: AlphaFold 3 for drug discovery: https://alphafoldserver.com OpenAI Agents and Agentic Workflows: https://platform.openai.com/docs/guides/agents Schrödinger computational drug discovery platform: https://www.schrodinger.com/platform Solo Founder's Journey: Building with AI: https://www.ycombinator.com/library/6f-building-a-solo-startup Economics of Pharmaceutical R&D (KFF): https://www.kff.org/rx-drugs/issue-brief/explaining-the-prescription-drug-pricing-process/ Agentic AI for Multi-Modality Drug Design (Nature): https://www.nature.com/articles/s41587-024-02371-6 Companies, Universities, & People Mentioned: Google: https://www.google.com DeepMind: https://deepmind.google OpenAI: https://openai.com Anthropic: https://www.anthropic.com Apollo: https://www.apollo.io Clay: https://www.clay.com ZoomInfo: https://www.zoominfo.com ElevenLabs: https://elevenlabs.io HubSpot: https://www.hubspot.com Wellcome Sanger Institute: https://www.sanger.ac.uk American Medical Association: https://www.ama-assn.org Endpoints News: https://endpts.com STAT News: https://www.statnews.com Linus Pauling: https://www.nobelprize.org/prizes/chemistry/1954/pauling/biographical/ Timestamps: 00:00 Intro 02:00 Knowing When to Leave Google 07:26 Solo Founding Pauling AI 08:11 Early Days Doing Everything 09:24 Solo Founding in the AI Age 10:53 Building With LLMs and Agents 14:20 Voice Agents and Human Latency 17:06 Premium on Human-Crafted Work 20:24 Regulation and Human Doctors…
Not rated yet🧬 From Games to Cancer Research: Why Drug Discovery Is an Economics Problem | Javier Tordable (3/4)
· 22 min
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners "Pessimists are often right, but optimists are often wealthy." In this part of the podcast, Jon and Javier explore Javier's years as technical director in Google's Office of the CTO, where he worked with the world's biggest gaming companies—Nintendo, Ubisoft, Electronic Arts, and Unity—helping them leverage Google Cloud technology. Javier then shares the deeply personal story of how his father's passing from cancer became the turning point that pulled him into life sciences, and how he taught himself biochemistry and pharmacology through Harvard Medical School's HMX program. The conversation takes a sharp turn into the economics of drug discovery and healthcare. Javier argues that the biggest failures in biotech are not scientific but economic—nobody wants to pay $10,000 for an antibiotic, so companies stop researching them. Jon and Javier unpack the misaligned incentives, administrative bloat, and rising costs that plague the US healthcare system, and debate whether AI can help solve problems that are fundamentally about money, not science. Key Topics Covered: - Working With Gaming Companies: How Javier partnered with Nintendo, Ubisoft, EA, and Unity as technical director in Google's CTO office. - From Gaming to Life Sciences: How the death of Javier's father from cancer became the turning point that redirected his career. - Self-Taught Biochemistry: Learning biochem, pharmacology, and physiology through Harvard Medical School's HMX courses while working at Google. - Life Sciences Gatekeeping: Why the field is uniquely unwelcoming to outsiders—and why Jon compares academic science to fiefdoms. - Drug Discovery Is an Economics Problem: Why the biggest barriers to new cures are funding, incentives, and economics—not science. - Antibiotics and the Profit Problem: Why no company will develop novel antibiotics because nobody will pay $10,000 for one. If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep262 Find our guest, Javier Tordable at these links: LinkedIn: https://www.linkedin.com/in/jtordable Website: https://www.pauling.ai/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Best practices for using Spanner as a gaming database: https://docs.cloud.google.com/spanner/docs/best-practices-gaming-database Biochemistry Fundamentals: https://learn.hms.harvard.edu/programs/biochemistry-fundamentals Computational Platform for Molecular Discovery & Design - Schrödinger: https://www.schrodinger.com/platform/ Why 90% of clinical drug development fails and how to improve it? - PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC9293739/ How Does Health Spending in the U.S. Compare to Other Countries? | KFF: https://www.kff.org/health-costs/health-spending-in-the-u-s-as-compared-to-other-countries-slideshow/ Current economic and regulatory challenges:…
Not rated yet🧬 16 Years at Google Taught Me How to Scale From 1 to 150 People | Javier Tordable (2/4)
· 28 min
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners "You had this combination of being able to move fast, make changes quickly, but at the same time, responsibility and empowerment." In this part of the podcast, Javier Tordable shares his early career journey—from starting at Microsoft to spending 16 years at Google as a Staff Engineer and Technical Director. He reflects on the engineering-driven culture at Microsoft and the welcoming environment that shaped his foundation in tech. Javier recounts joining Google in 2008 when the company was still under 25,000 people, and details his work building key features for Webmaster Tools (now Google Search Console), including the Fetch as Googlebot feature. He and Jon also swap stories about the scrappy early days of building products with limited resources. Key Topics Covered: - Javier's early career at Microsoft and its engineering-driven culture - Transitioning to Google in 2008 and the interview process - Building features for Webmaster Tools and Google Search Console - Google's culture of empowerment and moving fast - Comparing early startup resourcefulness with big-tech engineering scale If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep261 Find our guest, Javier Tordable at these links: LinkedIn: https://www.linkedin.com/in/jtordable Website: https://www.pauling.ai/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Engineering Leadership and Tech Lead Responsibilities: https://handbook.gitlab.com/handbook/engineering/careers/ic-leadership/tech-lead/ Google Search Console and Webmaster Tools: https://search.google.com/search-console/about Organizational Design in Tech Companies: https://a16z.com/scaling-your-technical-org/ Scaling Engineering Organizations and Process Documentation: https://stripe.com/guides/atlas/scaling-eng SEO Tools for Business Growth: https://www.semrush.com/seo/ Companies, Universities, & People Mentioned: Google: https://www.google.com Microsoft: https://www.microsoft.com Timestamps: 00:00 Intro 01:56 Adjusting to US Culture from Spain 04:06 Microsoft's Engineering-Driven Culture 05:20 Joining Google in the Post-IPO Era 06:40 How the Google Opportunity Came About 08:46 Working at Google: Speed and Scale 09:12 Building Webmaster Tools and Search Console 10:06 Jon's Early Days Starting Excedr 12:26 Transitioning to Ads as Staff Engineer 16:58 Management Roles and Team Leadership 18:59 Operating at Google's Massive Scale 20:29 Documentation and Knowledge Management 21:05 Office Culture and In-Person Collaboration 27:16 Outro The Biotech Startups Podcast gives you a front-row seat to the business and science of building a biotech. Hosted by Jon Chee, CEO of Excedr, the show features honest conversations with founders, execs, and investors about their work, their companies, and how they got there. From scientific breakthroughs to startup…
Not rated yet🧬 Video Games & a Whim Led Me to Microsoft | Javier Tordable (1/4)
· 26 min
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners "I think so many of us started playing video games as young adults or as teenagers. And that leads you to a path where you think, well, how does this work?" In this episode of The Biotech Startups Podcast, Jon Chee sits down with Javier Tordable, founder and CEO of Pauling AI, a company building the first fully autonomous drug discovery platform that enables scientists to go from a research idea to validated drug molecules in days, not years. Named after Linus Pauling, the only person in history to win two unshared Nobel Prizes, the company reflects Javier's conviction that first principles engineering can be applied to one of science's most consequential problems. Before founding Pauling AI, Javier spent sixteen years at Google, rising to staff engineer and serving as technical director in the office of the CTO, partnering with companies like Nintendo, Ubisoft, and Electronic Arts. In Part 1 of this four-part conversation, Javier traces his early years in 1990s Spain, where a love of video games sparked a self-taught journey into programming, a father who taught high school mathematics planted a deep love of the discipline, and a chance encounter with a university poster led to a Microsoft internship that permanently redirected his career. Key Topics Covered: - Early Years in Spain: How a childhood curiosity for science and engineering set the foundation for a career in technology. - Video Games as a Gateway: How playing classic LucasArts adventures and Nintendo 64 games sparked a self-taught journey into programming. - Self-Taught Programming: Navigating the early internet in 1990s Spain to learn Visual Basic and game development without formal instruction. - The Golden Age of Gaming: How the late 90s explosion of creative, risk-taking game development shaped a generation of technologists. - Gaming Skills in Modern Tech: How resource management and optimization instincts from games like StarCraft translate to managing AI agents today. - A Father's Influence: How a high school math teacher parent planted a deep love of mathematics that underpinned a career in computational science. If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 Youtube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep260 Find our guest, Javier Tordable at these links: LinkedIn: https://www.linkedin.com/in/jtordable Website: https://www.pauling.ai/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Operating Lease: https://www.excedr.com/blog/operating-lease Molecular Biology: https://www.excedr.com/blog/what-is-molecular-biology NDA Process: https://www.excedr.com/blog/new-drug-application-process IND Application: https://www.excedr.com/blog/ind-application-process FDA Drug Approval: https://www.excedr.com/blog/fda-drug-approval-process-guide Companies, Universities, & People Mentioned: Google: https://www.google.com Microsoft: https://www.microsoft.com…
Not rated yet🧬 Crossover Investing, Gene Therapy & LP Trust | Stephanie Sirota Rerelease (3/3)
· 30 min
🧬 The Biotech Startups Podcast is powered by Excedr-helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network-special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. "Drug development is not a linear process." In this episode of The Biotech Startups Podcast, host Jon Chee continues his conversation with Stephanie Sirota, Partner and Head of Strategic Partnerships at RTW Investments, as she traces RTW’s evolution from a lean public-equity fund into a major life sciences platform spanning crossover investing, company creation, and global commercialization. Stephanie explains how RTW built the modern crossover ecosystem, why they chose to found Rocket Pharma instead of a fleet of gene therapy startups, and how a disciplined, science-first research process underpins the firm’s long-term, concentrated investing strategy and deep alignment with LPs and portfolio founders. Key Topics Covered: - Building the biotech crossover investing ecosystem: RTW’s early role in late-stage private rounds. - Gene therapy deep dives & Rocket Pharma: Why RTW built one platform company instead of many. - Thesis-driven company creation in China: Licensing Western assets to tackle cardiovascular & ophthalmology. - Conviction, position sizing & non-linear drug development: How RTW underwrites multiple inflection points. - Educating LPs & tracking a 60% batting average: Process, data libraries & domain expertise. - Navigating cycles with transparency & trust: Berkshire-style moments, metabolic disease opportunities & backing science through downturns. If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep259 Find our guest, Stephanie Sirota at these links: LinkedIn: https://www.linkedin.com/in/stephsirota/ Website: https://www.rtwfunds.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Jesse Gelsinger case & early gene therapy: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907126/ AveXis (Zolgensma) gene therapy overview: https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avexis-inc-expand-leadership-gene-therapy Rocket Pharmaceuticals pipeline overview: https://www.rocketpharma.com/pipeline/ GLP-1 receptor agonists in metabolic disease: https://www.nejm.org/doi/full/10.1056/NEJMra1907937 Metabolic disease & obesity drug landscape: https://www.nature.com/articles/s41574-021-00556-9 Biotech market benchmark XBI profile: https://www.ssga.com/us/en/institutional/etfs/spdr-sp-sbx-biotech-etf-xbi IMG Academy tennis training program: https://www.imgacademy.com/sport-camps/tennis Companies, Universities, & People Mentioned: RTW Investments: https://www.rtwfunds.com/ AveXis: https://www.novartis.com/our-products/avexis Novartis: https://www.novartis.com Rocket Pharmaceuticals: https://www.rocketpharma.com/ Ji Xing Pharmaceuticals: https://www.jxpharma.com/ IMG Academy: https://www.imgacademy.com/ Lehman Brothers (archived): https://www.lehman.com Valhalla Capital Management: https://www.valhallacap.com/ Berkshire Hathaway:…
Not rated yet🧬 Cycles, Conviction & Royalty Capital in Biotech Investing | Stephanie Sirota Rerelease (2/3)
· 32 min
🧬 The Biotech Startups Podcast is powered by Excedr-helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network-special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. "When you're at the top of your game, you have to change your game." In this episode of The Biotech Startups Podcast, host Jon Chee continues his conversation with Stephanie Sirota, Partner and Head of Strategic Partnerships at RTW Investments, as she reflects on her path from Lehman Brothers investment banking to macro hedge funds and ultimately biotech-focused investing and firm building. Steph shares how journalism training shaped her strategic thinking, what she learned from navigating multiple market crises, and how those lessons inform RTW’s approach to cycles, institutional architecture, and innovative funding models like royalty vehicles in today’s prolonged biotech bear market. Key Topics Covered: - Sell Side vs. Buy Side: A clear breakdown of advisory banking, hedge funds, and fiduciary capital. - Mentorship & Inflection Points: How candid feedback at Lehman unlocked Steph’s strategic strengths. - Pivoting to the Buy Side: Institutionalizing a macro hedge fund and building firm architecture. - Entering Biotech: Meeting Rod Wong, learning science in a slower era, and falling in love with the sector. - Navigating Market Cycles: Dot-com, 2008, and today’s biotech bear market through a “steady hand” lens. - Innovating Capital Structures: RTW’s royalty fund & non-dilutive financing for emerging biotech companies. If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep258 Find our guest, Stephanie Sirota at these links: LinkedIn: https://www.linkedin.com/in/stephsirota/ Website: https://www.rtwfunds.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Legacy: What the All Blacks Can Teach Us About the Business of Life: https://www.hachettebookgroup.com/titles/james-kerr/legacy/9781472103536/ RTW Investments Royalty & Credit Strategy Overview: https://www.rtwfunds.com/royalty-and-credit RNA Interference: Gene Silencing by Double-Stranded RNA: https://www.nature.com/articles/35079145 Global Financial Crisis Overview: https://www.imf.org/external/pubind/glofincrisis/ Dot-Com Bubble Background: https://www.investopedia.com/terms/d/dotcom-bubble.asp Companies, Universities, & People Mentioned: Lehman Brothers: https://www.lehman.com Columbia University: https://www.columbia.edu Nestlé: https://www.nestle.com PepsiCo: https://www.pepsico.com L'Oréal: https://www.loreal.com RTW Investments: https://www.rtwfunds.com Valhalla Capital Management: https://www.valhallacapital.com Goldman Sachs: https://www.goldmansachs.com Davidson Kempner Capital Management: https://www.davidsonkempner.com All Blacks (New Zealand Rugby): https://www.allblacks.com FTC (Federal Trade Commission): https://www.ftc.gov FDA (U.S. Food & Drug Administration): https://www.fda.gov Timestamps: 00:00 Intro 01:33 Journalism training, Lehman London & consumer M&A 03:30 What investment banking is…
Not rated yet🧬 Competition, Coaching & Curiosity: The Investor’s Mindset | Stephanie Sirota Rerelease (1/3)
· 24 min
🧬 The Biotech Startups Podcast is powered by Excedr-helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network-special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. "You learn more from the questions than actually from the answers." In this episode of The Biotech Startups Podcast, Jon Chee sits down with Stephanie Sirota, partner and head of strategic partnerships at RTW Investments, to explore how a coddled yet cosmopolitan upbringing, years of elite tennis competition, and a humanities-rich education at Columbia shaped her mental toughness, leadership style, and approach to partnering with life sciences innovators. From sports psychology and coaching to the value of breadth before specialization, Stephanie reflects on the experiences that built her resilience and curiosity long before she helped transform RTW into a leading life sciences investment firm. Key Topics Covered: - Early upbringing & cultural exposure: How time in Europe and Argentina fostered observation, listening, and empathy. - Competitive tennis & mental toughness: Lessons from Nick Bollettieri’s academy, sports psychology, and learning to never give up. - Coaching, feedback & leadership: Why the right coaches and boards are critical for executives & company builders. - Burnout, injury & reinvention: Transitioning from a potential pro tennis career to SMU and then Columbia University. - Columbia core curriculum & humanities: How the Western canon, philosophy, and broad education inform strategy & investing. - Journalism training & investment banking: Using storytelling, information triage, and capital to drive impact in biotech investing. If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep257 Find our guest, Stephanie Sirota, at these links: LinkedIn: https://www.linkedin.com/in/stephsirota/ Website: https://www.rtwfunds.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: Nick Bollettieri Tennis Academy (IMG Academy Tennis): https://www.imgacademy.com/sport-camps/tennis Jim Loehr – Sports Psychology & Mental Toughness: https://www.jim-loehr.com Columbia College Core Curriculum: https://www.college.columbia.edu/core Western Canon (Literature & Humanities Overview): https://plato.stanford.edu/entries/literary-theory Bioethics Overview (Research Ethics): https://www.nuffieldbioethics.org/resources/bioethics-briefing-notes Investment Banking Overview (M&A, IPOs & Capital Markets): https://www.investopedia.com/terms/i/investment-banking.asp Companies, Universities, & People Mentioned: RTW Investments: https://www.rtwfunds.com Lehman Brothers (historical archive): https://www.britannica.com/topic/Lehman-Brothers Valhalla Capital Advisors: https://www.valhallacap.com IMG Academy (formerly Nick Bollettieri Tennis Academy): https://www.imgacademy.com Southern Methodist University (SMU): https://www.smu.edu Columbia University: https://www.columbia.edu University of California, Berkeley: https://www.berkeley.edu Timestamps: 00:00 Intro 00:57 Stephanie’s globally…
Not rated yet🧬 Transforming Food Systems with Lactoferrin & Precision Fermentation | Fengru Lin Rerelease (3/3)
· 28 min
🧬 The Biotech Startups Podcast is powered by Excedr-helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science. As a TBSP listener, you can get exclusive perks through Excedr's partner network-special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. "Our vision is really to transform the food system. We want to be able to nourish and nurture people, the planet, and animals, and we do that by producing better-for-you ingredients through sustainable methods." In this episode of The Biotech Startups Podcast, Jon Chee sits down with Fengru Lin, CEO & co-founder of TurtleTree, who is leveraging precision fermentation and a people-first culture to bring the high-value milk protein lactoferrin to market while reshaping how the food system serves both consumers and farmers. They discuss TurtleTree's strategic refocus from cell-based milk to commercially viable ingredients, the importance of business-centric leadership in biotech, and how thoughtful team-building enables faster execution, better fundraising narratives, and earlier commercialization. Key Topics Covered: - Transforming the food system: TurtleTree’s vision, mission, and B2B2C positioning. - People as core assets: Early HR leadership, culture-building, and empowering world-class scientists. - Strategic refocus: Moving from cell-based milk toward precision fermentation & lactoferrin. - Commercialization strategy: B2B sales, product integration, and “Intel Inside”-style branding. - Food system impact: Price volatility, farmer pressures, and lactose-free & plant-based applications. - Fundraising & leadership: Navigating tough markets, investor skepticism, and business-led biotech. If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening. Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994 Spotify: https://open.spotify.com/show/2PSL162R2s0zOwU5913Zv4 YouTube: https://www.youtube.com/@thebiotechstartupspodcast Website: https://www.thebiotechstartupspodcast.com/?utm_source=podcast&utm_medium=show-notes&utm_campaign=the-biotech-startups-podcast-ep256 Find our guest, Fengru Lin, at these links: LinkedIn: https://www.linkedin.com/in/fengru/ Website: https://www.turtletree.com/ Find our host, Jon Chee, at these links: LinkedIn: https://www.linkedin.com/in/jonchee/ Learn more about Excedr: LinkedIn: https://www.linkedin.com/company/excedr/ Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: SupplySide West ingredients conference: https://www.supplysidewest.com IFT FIRST Annual Event and Expo (Chicago food conference): https://www.ift.org/events/ift-first-annual-event-and-expo World Economic Forum feature on lactoferrin & precision fermentation: https://www.facebook.com/worldeconomicforum/posts/lactoferrin-supports-immunity-boosts-gut-health-and-improves-digestion-but-right/1441804124654488 Global Dairy Trade lactoferrin pricing overview: https://www.globaldairytrade.info Merck KGaA company overview: https://www.merckgroup.com Dow Corporate company overview: https://corporate.dow.com/en-us.html Thermo Fisher Scientific company overview: https://www.thermofisher.com Companies, Universities, & People Mentioned: TurtleTree: https://www.turtletree.com Abbott: https://www.abbott.com Fonterra: https://www.fonterra.com Merck KGaA: https://www.merckgroup.com Dow: https://corporate.dow.com/en-us.html Thermo Fisher Scientific: https://www.thermofisher.com Salesforce: https://www.salesforce.com Google: https://www.google.com Excedr: https://www.excedr.com Timestamps: 00:00 Intro 01:37 TurtleTree’s mission to transform the food system 02:22…
Not rated yet